Literature DB >> 18679425

Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays.

D S Rickman1, R Millon, A De Reynies, E Thomas, C Wasylyk, D Muller, J Abecassis, B Wasylyk.   

Abstract

Propensity for subsequent distant metastasis in head and neck squamous-cell carcinoma (HNSCC) was analysed using 186 primary tumours from patients initially treated by surgery that developed (M) or did not develop (NM) metastases as the first recurrent event. Transcriptome (Affymetrix HGU133_Plus2, QRT-PCR) and array-comparative genomic hybridization data were collected. Non-supervised hierarchical clustering based on Affymetrix data distinguished tumours differing in pathological differentiation, and identified associated functional changes. Propensity for metastasis was not associated with these subgroups. Using QRT-PCR data we identified a four-gene model (PSMD10, HSD17B12, FLOT2 and KRT17) that predicts M/NM status with 77% success in a separate 79-sample validation group of HNSCC samples. This prediction is independent of clinical criteria (age, lymph node status, stage, differentiation and localization). The most significantly altered transcripts in M versus NM were significantly associated to metastasis-related functions, including adhesion, mobility and cell survival. Several genomic modifications were significantly associated with M/NM status (most notably gains at 4q11-22 and Xq12-28; losses at 11q14-24 and 17q11 losses) and partly linked to transcription modifications. This work yields a basis for the development of prognostic molecular signatures, markers and therapeutic targets for HNSCC metastasis.

Entities:  

Mesh:

Year:  2008        PMID: 18679425     DOI: 10.1038/onc.2008.251

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  70 in total

1.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Authors:  Mark P Labrecque; Ilsa M Coleman; Lisha G Brown; Lawrence D True; Lori Kollath; Bryce Lakely; Holly M Nguyen; Yu C Yang; Rui M Gil da Costa; Arja Kaipainen; Roger Coleman; Celestia S Higano; Evan Y Yu; Heather H Cheng; Elahe A Mostaghel; Bruce Montgomery; Michael T Schweizer; Andrew C Hsieh; Daniel W Lin; Eva Corey; Peter S Nelson; Colm Morrissey
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

2.  Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Authors:  Ronald C Hendrickson; Vito R Cicinnati; Andreas Albers; Grzegorz Dworacki; Andrea Gambotto; Ornella Pagliano; Thomas Tüting; Jose I Mayordomo; Carmen Visus; Ettore Appella; Jeffrey Shabanowitz; Donald F Hunt; Albert B DeLeo
Journal:  Cancer Immunol Immunother       Date:  2009-06-27       Impact factor: 6.968

3.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.

Authors:  Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

4.  High expression of flotillin-2 is associated with poor clinical survival in cervical carcinoma.

Authors:  Yaqiong Liu; Li Lin; Zijian Huang; Bing Ji; Shanshan Mei; Ying Lin; Zhuanxing Shen
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells.

Authors:  Caroline W Fugle; Yongliang Zhang; Feng Hong; Shaoli Sun; Caroline Westwater; Saleh Rachidi; Hong Yu; Elizabeth Garret-Mayer; Keith Kirkwood; Bei Liu; Zihai Li
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

6.  Proteomics-based Predictive Model for the Early Detection of Metastasis and Recurrence in Head and Neck Cancer.

Authors:  Ilda Patrícia Ribeiro; Luísa Esteves; Sandra Isabel Anjo; Francisco Marques; Leonor Barroso; Bruno Manadas; Isabel Marques Carreira; Joana Barbosa Melo
Journal:  Cancer Genomics Proteomics       Date:  2020 May-Jun       Impact factor: 4.069

7.  Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  David A Rodeberg; Norbert Garcia-Henriquez; Elizabeth R Lyden; Elai Davicioni; David M Parham; Stephen X Skapek; Andrea A Hayes-Jordan; Sarah S Donaldson; Kenneth L Brown; Timothy J Triche; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

8.  17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.

Authors:  Marta Szajnik; Miroslaw J Szczepanski; Esther Elishaev; Carmen Visus; Diana Lenzner; Maciej Zabel; Marta Glura; Albert B DeLeo; Theresa L Whiteside
Journal:  Gynecol Oncol       Date:  2012-08-17       Impact factor: 5.482

9.  ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines.

Authors:  C Ayoub; C Wasylyk; Y Li; E Thomas; L Marisa; A Robé; M Roux; J Abecassis; A de Reyniès; B Wasylyk
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

10.  Should we abandon the t-test in the analysis of gene expression microarray data: a comparison of variance modeling strategies.

Authors:  Marine Jeanmougin; Aurelien de Reynies; Laetitia Marisa; Caroline Paccard; Gregory Nuel; Mickael Guedj
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.